RU98120519A - AUTOANTIGEN AND STRUCTURAL-RELATED PROTEINS FOR USE IN IMMUNOTHERAPY OF AUTOIMMUNE DISEASES - Google Patents

AUTOANTIGEN AND STRUCTURAL-RELATED PROTEINS FOR USE IN IMMUNOTHERAPY OF AUTOIMMUNE DISEASES

Info

Publication number
RU98120519A
RU98120519A RU98120519/14A RU98120519A RU98120519A RU 98120519 A RU98120519 A RU 98120519A RU 98120519/14 A RU98120519/14 A RU 98120519/14A RU 98120519 A RU98120519 A RU 98120519A RU 98120519 A RU98120519 A RU 98120519A
Authority
RU
Russia
Prior art keywords
protein
amino acid
acid sequence
homology
exhibits
Prior art date
Application number
RU98120519/14A
Other languages
Russian (ru)
Other versions
RU2189248C2 (en
Inventor
Анна Мария Хелена Ботс
Гейсбертус Франсискус Мария Верхейден
Эбо Сибрен Бос
Original Assignee
Акцо Нобель Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/634,493 external-priority patent/US5843449A/en
Application filed by Акцо Нобель Н.В. filed Critical Акцо Нобель Н.В.
Publication of RU98120519A publication Critical patent/RU98120519A/en
Application granted granted Critical
Publication of RU2189248C2 publication Critical patent/RU2189248C2/en

Links

Claims (11)

1. Белок, содержащий аминокислотную последовательность, обнаруживающую по меньшей мере 50% гомологию с аминокислотной последовательностью YKLVCYYTSWSQYREGDGSCFPDALDRFLCTHIIYSFANISND (ПОСЛЕД. N 1), для применения в качестве лекарственного вещества.1. A protein containing an amino acid sequence that exhibits at least 50% homology with the amino acid sequence YKLVCYYTSWSQYREGDGSCFPDALDRFLCTHIIYSFANISND (SEQ. N 1) for use as a medicament. 2. Белок по п. 1, отличающийся тем, что указанный белок является 39 кД белком сыворотки быка или человеческим белком YKL-39. 2. The protein according to claim 1, characterized in that said protein is a 39 kD bovine serum protein or human YKL-39 protein. 3. Фармацевтическая композиция, содержащая один или несколько белков, содержащих аминокислотную последовательность, обнаруживающую по меньшей мере 50% гомологию с аминокислотной последовательностью YKLVCYYTSWSQYREGDGSCFPDALDRFLCTHIIYSFANISND (ПОСЛЕД. N 1), и фармацевтически приемлемый носитель. 3. A pharmaceutical composition comprising one or more proteins containing an amino acid sequence that exhibits at least 50% homology with the amino acid sequence YKLVCYYTSWSQYREGDGSCFPDALDRFLCTHIIYSFANISND (SEQ. N 1), and a pharmaceutically acceptable carrier. 4. Фармацевтическая композиция по п. 3, отличающаяся тем, что указанный белок является 39 кД белком сыворотки быка или человеческим белком YKL-39. 4. The pharmaceutical composition according to claim 3, characterized in that said protein is a 39 kD bovine serum protein or human YKL-39 protein. 5. Применение белка, содержащего аминокислотную последовательность, обнаруживающую по меньшей мере 50% гомологию с аминокислотной последовательностью YKLVCYYISWSQYREGDGSCFPDALDRFLCTHIIYSFANISND (ПОСЛЕД. N 1), для производства фармацевтического препарата для индукции специфической Т-клеточной толерантности к гомологичному аутоантигену у млекопитающих, страдающих от опосредованного T-клетками разрушения хряща. 5. The use of a protein containing an amino acid sequence that exhibits at least 50% homology with the amino acid sequence YKLVCYYISWSQYREGDGSCFPDALDRFLCTHIIYSFANISND (SEQ. N 1), for the manufacture of a pharmaceutical preparation for the induction of specific T cell tolerance to a homologous autoantigen antigen T cartilage destruction. 6. Применение по п. 5, отличающийся тем, что указанный белок является 39 кД белком сыворотки быка или человеческим белком YKL-39. 6. The use of claim 5, wherein said protein is a 39 kD bovine serum protein or human YKL-39 protein. 7. Способ индукции артрита у животных, предпочтительно - у мышей, включающий обработку указанных животных активным агентом, отличающийся тем, что названный активный агент представляет собой один или несколько белков, содержащих аминокислотную последовательность, обнаруживающую, по крайней мере, 50% гомологию с аминокислотной последовательностью YKLVCYYTSMSQYREGDGSCFPDALDRFLCTHIIYSFANISND (ПОСЛЕД. N 1). 7. A method of inducing arthritis in animals, preferably in mice, comprising treating said animals with an active agent, characterized in that said active agent is one or more proteins containing an amino acid sequence that exhibits at least 50% homology with the amino acid sequence YKLVCYYTSMSQYREGDGSCFPDALDRFLCTHIIYSFANISND (LAST N 1). 8. Способ по п. 7, отличающийся тем, что указанный белок является 30 кД белком сыворотки быка или человеческим белком YKL-39. 8. The method according to p. 7, characterized in that said protein is a 30 kD bovine serum protein or human YKL-39 protein. 9. Белок с аминокислотной последовательностью, представленной в ПОСЛЕД. N 2. 9. A protein with the amino acid sequence presented in the AFTER. N 2. 10. Выделенная ДНК, кодирующая аминокислотную последовательность по п. 9. 10. The selected DNA encoding the amino acid sequence according to p. 9. 11. Выделенная ДНК по п. 10, отличающаяся тем, что имеет последовательность, представленную в ПОСЛЕД. 3. 11. The isolated DNA according to p. 10, characterized in that it has the sequence presented in the AFTER. 3.
RU98120519/14A 1996-04-18 1997-04-15 Autoantigen and structurally related proteins for using in immunotherapy of autoimmune diseases RU2189248C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/634,493 1996-04-18
US08/634.493 1996-04-18
US08/634,493 US5843449A (en) 1996-03-25 1996-04-18 Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases

Publications (2)

Publication Number Publication Date
RU98120519A true RU98120519A (en) 2000-09-20
RU2189248C2 RU2189248C2 (en) 2002-09-20

Family

ID=24544023

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98120519/14A RU2189248C2 (en) 1996-04-18 1997-04-15 Autoantigen and structurally related proteins for using in immunotherapy of autoimmune diseases

Country Status (16)

Country Link
US (1) US5843449A (en)
EP (1) EP0904369A1 (en)
JP (1) JP2000509265A (en)
KR (1) KR20000005476A (en)
CN (1) CN1216582A (en)
AU (1) AU724547B2 (en)
BR (1) BR9708714A (en)
CA (1) CA2251584A1 (en)
CZ (1) CZ333398A3 (en)
HU (1) HU221348B1 (en)
NO (1) NO984835L (en)
NZ (1) NZ332311A (en)
PL (1) PL187451B1 (en)
RU (1) RU2189248C2 (en)
TR (1) TR199802082T2 (en)
WO (1) WO1997040149A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5928928A (en) * 1995-06-07 1999-07-27 Universiteit Van Amsterdam Human chitinase, its recombinant production, its use for decomposing chitin, its use in therapy or prophylaxis against infection diseases
EP1100526A2 (en) * 1998-07-23 2001-05-23 Akzo Nobel N.V. USE OF HC gp-39 IN IMMUNE DISEASES
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd Immunological and oral tolerance-inducing composition and use thereof for the prevention and/or for the treatment of atherosclerosis
US20020102581A1 (en) * 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US7011952B2 (en) * 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
DE60136272D1 (en) * 2000-04-29 2008-12-04 Univ Iowa Res Found DIAGNOSTICS AND THERAPEUTICS FOR MACULAR DEGENERATION DISEASES
CN1352087A (en) * 2000-11-02 2002-06-05 上海博德基因开发有限公司 New polypeptide-human glycoprotein 42 and polynucleotide for encoding such polypeptide
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
US7265208B2 (en) * 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
US8195187B2 (en) 2001-06-25 2012-06-05 Airvana Network Solutions, Inc. Radio network control
US8160020B2 (en) 2001-06-25 2012-04-17 Airvana Network Solutions, Inc. Radio network control
BR0211468A (en) * 2001-07-24 2004-11-23 Univ Yale Methods of Treating and Preventing an Inflammatory Disease in a Mammal and Identifying a Compound Useful for Treating an Inflammatory Disease in a Mammal, Compound, and Kits for Treating and Preventing an Inflammatory Disease in a Mammal
WO2005081980A2 (en) * 2004-02-25 2005-09-09 Medimmune, Inc. Methods and compositions relating to chitinases and chitinase-like molecules and modulation of osteoclasts
US8099504B2 (en) 2005-06-24 2012-01-17 Airvana Network Solutions, Inc. Preserving sessions in a wireless network
WO2007027748A2 (en) * 2005-08-31 2007-03-08 Medimmune, Inc. C/clp antagonists and methods of use thereof
US7751835B2 (en) 2005-10-04 2010-07-06 Airvana, Inc. Non-circular paging areas
US8094630B2 (en) 2005-12-16 2012-01-10 Airvana Network Solutions, Inc. Radio frequency dragging prevention
US8619702B2 (en) 2005-12-16 2013-12-31 Ericsson Evdo Inc. Radio network control
US8145221B2 (en) 2005-12-16 2012-03-27 Airvana Network Solutions, Inc. Radio network communication
US8085696B2 (en) 2006-07-14 2011-12-27 Airvana Networks Solutions, Inc. Dynamic modification of route update protocols
US8843638B2 (en) 2007-12-13 2014-09-23 Ericsson Evdo Inc. Handing off active connections
MX2011001371A (en) 2008-08-05 2011-06-16 Novartis Ag Compositions and methods for antibodies targeting complement protein c5.
EP3102701A1 (en) 2014-02-07 2016-12-14 Novartis AG Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
JP6671363B2 (en) 2014-07-15 2020-03-25 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミティッド Isolated polypeptide of CD44 and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284623A (en) * 1979-11-09 1981-08-18 Beck Lee R Method of treating inflammation using bovine milk
JPS6323898A (en) * 1986-07-16 1988-02-01 Dainippon Pharmaceut Co Ltd Novel polypeptide, dna coding said polypeptide and production thereof
CA2164498C (en) * 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
BR9507452A (en) * 1994-04-08 1997-08-05 Brigham & Womens Hospital Pharmaceutical composition use of a non-interferon polypeptide use of a quantity of a standardized antigen and a quantity of a non-interferon polypeptide and product containing (1) a quantity of a standardized antigen and (11) a quantity of a non-interferon polypeptide
IL115744A (en) * 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39

Similar Documents

Publication Publication Date Title
RU98120519A (en) AUTOANTIGEN AND STRUCTURAL-RELATED PROTEINS FOR USE IN IMMUNOTHERAPY OF AUTOIMMUNE DISEASES
Julliard et al. High-molecular-weight immunoreactive β-endorphin in extracts of human placenta is a fragment of immunoglobulin G
EP2848627A3 (en) Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
NZ332311A (en) Use of autoantigen HC gp-39 and proteins structurally related thereto in immunotherapy of autoimmune diseases particularly rheumatoid arthritis
RU2000131593A (en) SELECTIVE AGONISTS AND ANTAGONISTS IL-2.
AR018603A1 (en) A PEPTIDE, USEFUL FOR THE TREATMENT AND / OR PROFILAXIS OF ALZHEIMER'S DISEASE AND THE DOWN SYNDROME, PHARMACEUTICAL COMPOSITIONS AND VACCINES WHICH LOCATE, THE USE OF SUCH PEPTIDE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS OF DNA, SECTION A PLASMID OR VECTOR VI
JP2003528827A5 (en)
RU2010120571A (en) THYMUS SPECIFIC PROTEIN
EP2371847A1 (en) Peptides and their derived type APL of the HSP60 and pharmaceutical compositions
RU97105374A (en) MODIFIED PROTEINS
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
JPH05506247A (en) Antagonist of human gamma interferon
WO2006031727A2 (en) Peptides for treatment of autoimmune diseases
US20070264229A1 (en) Peptides for Treatment of Autoimmune Disease
EA027229B1 (en) Peptide which is a fragment of factor viii, and composition for suppressing or preventing the production of factor viii inhibitor antibodies in vivo
ATE310828T1 (en) IMPLANT AND VECTOR FOR THE TREATMENT OF ACQUIRED DISEASES
HUP0102975A2 (en) Chemotaxis-inhibiting protein of staphylococcus (chips) and its use
DE69837265D1 (en) POLYPEPTIDES FOR REGENERATING THE NERVOUS SYSTEM
IE863281L (en) Human placenta angiogenic factor capable of stimulating¹capillary endothelial cell protease synthesis, DNA synthesis¹and migration.
MXPA01011158A (en) Growth factor homolog zvegf4.
Low et al. Thymosins: Isolation, structural studies, and biological activities
HUP0001057A2 (en) Bovine lactation associated immunotropic protein (cd14), encoding gene and application in b cell activation
DE69330348D1 (en) Use of peptides which cause an immune response in the manufacture of medicaments for inducing immunosuppression.
RU2001105086A (en) NEW PEPTIDES FOR APPLICATION IN IMMUNOTHERAPY OF AUTOIMMUNE DISEASES
CA2163805A1 (en) Novel activating factor of leukocytes